Welcome to our dedicated page for MCKESSON SEC filings (Ticker: MCK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MCKESSON's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MCKESSON's regulatory disclosures and financial reporting.
McKesson Corporation Chief Executive Officer Brian S. Tyler reported equity compensation activity involving company stock. On 2026-05-19, he received 27,863 shares of Common Stock at $0.0000 per share as a grant related to the settlement of performance stock units that vested upon attainment of performance goals. In connection with this settlement, 10,937 shares of Common Stock were withheld at $761.89 per share to cover applicable taxes, a non‑market, tax-withholding disposition.
After these transactions, he directly held 31,875 shares of Common Stock and also received a separate grant of 9,739 Restricted Stock Units (RSUs), each representing one share of Common Stock, which will vest in three equal installments on 06/01/2027, 06/01/2028, and 06/01/2029. He also reported 215.8028 shares of Common Stock held indirectly through the McKesson Corporation 401(k) Retirement Savings Plan.
McKesson Corporation EVP & CFO Britt J. Vitalone reported routine equity compensation activity. On May 19, 2026, performance stock units vested and settled into 8,979 shares of common stock, increasing his direct holdings.
To cover taxes on this PSU settlement, 3,338 shares were withheld by the company, a non-market disposition that does not represent an open-market sale. After these transactions, Vitalone directly holds 19,669.377 shares of common stock and indirectly holds 552.2847 shares through the McKesson Corporation 401(k) Retirement Savings Plan.
MCKESSON CORP executive LeAnn B. Smith reported routine equity compensation activity. She received a grant of 4,129 shares of common stock and 1,471 restricted stock units on May 19, 2026, both at a stated price of $0.0000 per share as compensation awards.
On the same date, 1,523 shares of common stock were disposed of at $761.8900 per share to cover taxes linked to the settlement of performance stock units that had vested upon achievement of performance goals. After the stock grant, one line in the filing shows she directly held 5,595 common shares. The 1,471 RSUs will vest in three equal annual installments on June 1, 2027, June 1, 2028, and June 1, 2029.
MCKESSON CORP executive Thomas L. Rodgers reported equity compensation changes. On May 19, 2026, he received a grant of 3,614 shares of Common Stock at no cost and 919 Restricted Stock Units (RSUs), each RSU representing a right to receive one share of common stock.
On the same date, 1,226 common shares were withheld in a tax-withholding disposition at $761.89 per share to cover taxes tied to the settlement of performance stock units that vested upon attainment of performance goals. Following these transactions, he directly holds 4,656 common shares and 919 RSUs.
MCKESSON CORP EVP and Chief Legal Officer Michele Lau reported compensation-related equity transactions in company stock. On May 19, 2026, she received 4,454 shares of common stock as a grant or award and held 7,701 shares directly afterward.
On the same date, 1,753 common shares at $761.89 per share were disposed of as a tax-withholding transaction tied to the settlement of performance stock units, leaving 5,948 direct shares after that entry. She also received 1,969 Restricted Stock Units (RSUs), which will vest in three equal installments on June 1, 2027, June 1, 2028, and June 1, 2029, and she holds 139.0343 shares indirectly through the McKesson Corporation 401(k) Retirement Savings Plan.
MCKESSON CORP senior vice president and chief accounting officer Napoleon B. Rutledge Jr. reported compensation-related equity activity. On May 19, 2026, performance stock units vested, and 234 shares of common stock were withheld at $761.89 per share to cover related taxes.
On the same date, he received a grant of 788 shares of common stock and 211 restricted stock units, all held directly. The 211 RSUs are scheduled to vest in three equal installments on June 1, 2027, June 1, 2028, and June 1, 2029, reflecting ongoing long-term incentive compensation rather than open-market trading.
MCKESSON CORP executive Francisco Fraga reported equity compensation changes, not open-market trades. On May 19, 2026, he received 2,339 and 788 shares of common stock as grants tied to performance stock units that vested when performance goals were met. To cover related tax obligations, 843 and 192 shares of common stock were withheld at a price of $761.89 per share. Following these transactions, he holds 5,556.417 common shares directly and was granted 1,576 Restricted Stock Units that will convert into common stock in equal thirds on June 1, 2027, June 1, 2028, and June 1, 2029.
McKesson Corporation files its annual report describing a diversified healthcare services business organized into four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical‑Surgical Solutions.
The company plans to separate its Medical‑Surgical Solutions segment into an independent company and has agreed to sell a 13% minority stake in that segment to Apollo-managed funds for about $1.25 billion in convertible preferred equity, subject to approvals. McKesson completed the sale of its Norwegian operations, continues to rely heavily on large customers such as CVS, and highlights extensive regulatory, litigation, cybersecurity, and AI-related risks. It reports increasing investments in automation, data, and early-stage AI to boost efficiency and support its oncology, biopharma, and technology-enabled offerings.
McKesson Corporation reported strong fourth quarter and fiscal 2026 results, raised capital returns, and issued upbeat guidance. Full-year consolidated revenues were $403.4 billion, up 12%, while earnings per diluted share rose to $38.38 from $25.72. Adjusted Earnings per Diluted Share reached $39.11, an 18% increase, above the company’s previously communicated long-range growth targets.
Free Cash Flow was $5.4 billion, and McKesson returned $5.1 billion to shareholders through $4.8 billion of share repurchases and $381 million of dividends. The board added $5.0 billion to the share repurchase program, bringing authorization to $7.7 billion, and the company entered a $2.25 billion accelerated repurchase. For fiscal 2027, McKesson set Adjusted Earnings per Diluted Share guidance of $43.80 to $44.60, implying 12% to 14% growth, and reaffirmed its long-term adjusted EPS growth target of 13% to 16%.
McKesson Corp: Vanguard Capital Management reports beneficial ownership of 7.49% of common stock, equal to 9,180,981 shares as of 03/31/2026. The filing states Vanguard Capital Management exercises sole dispositive power over 9,180,981 shares and sole voting power for 1,220,257 shares. The holding includes securities held for Vanguard funds and managed accounts, described "in accordance with SEC Release No. 34-39538 (January 12, 1998)."